Stockscreener 앱 받기
1.49
1.97%
-0.03
시간 외 거래:
1.49
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Oppenheimer Initiates Acrivon Therapeutics(ACRV.US) With Buy Rating, Announces Target Price $8 - Moomoo
Acrivon Therapeutics (ACRV) Shows Modest Upside Amidst Key Technical LevelsDealer Delta - newsline.com
ACRV Stock Price, Quote & Chart - ChartMill
Acrivon Therapeutics (ACRV) Faces Continued Pressure, Testing Key Support After 7.7% DeclinePercent Above MA - newsline.com
Acrivon Therapeutics (ACRV) Slides 7.7% as Support Test Looms After Bearish MomentumDealer Positioning - newsline.com
ACRV Q1 2026 Earnings: EPS Beats Estimates as Clinical Pipeline AdvancesEPS Estimate Trend - newsline.com
ACRV Q1 2026 Earnings: Positive EPS Surprise Amid Pre-Revenue Pipeline ProgressEarnings Acceleration Picks - newsline.com
Acrivon Therapeutics (ACRV) Slides 1.23% as Stock Tests Key Support at $1.53Pairs Trade - The Legal Advocate
Acrivon Therapeutics Q1 2026 Earnings: Narrower Loss Per Share as Pipeline Progress ContinuesSurprise Factor Analysis - The Legal Advocate
Acrivon Therapeutics (ACRV) Edges Higher: Biotech Stock Tests Key Resistance at $1.77Double EMA - newsline.com
Acrivon (ACRV) CEO and EVP report RSU-related tax withholding move - Stock Titan
Acrivon Therapeutics (ACRV) Slides 1.71% as Stock Nears Critical Support ZoneDollar Neutral Pair - The Legal Advocate
Acrivon Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineDividend Increase Stocks - newsline.com
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline By Investing.com - Investing.com Australia
Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation Summit - Quiver Quantitative
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - The Manila Times
9,366 RSUs granted to Acrivon (ACRV) director for RA Capital funds - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units as equity award - Stock Titan
Director at Acrivon Therapeutics (ACRV) awarded 9,366 RSUs vesting 2027 - Stock Titan
Acrivon Therapeutics (ACRV) director receives 9,366 RSUs vesting in 2027 - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units in equity grant - Stock Titan
Acrivon Therapeutics (ACRV) CFO awarded 46,167 RSUs, holdings rise to 67,150 shares - Stock Titan
Acrivon Therapeutics (ACRV) director receives 9,366 RSUs award - Stock Titan
Acrivon Therapeutics (ACRV) director granted 9,366 restricted stock units - Stock Titan
Acrivon Therapeutics (ACRV) CAO awarded 14,227 RSUs in equity grant - Stock Titan
Acrivon Therapeutics (ACRV) CMO receives 38,817-share restricted stock unit grant - Stock Titan
Acrivon Therapeutics (ACRV) grants 49,830 RSUs to Chief Legal Officer Mary Miller - Stock Titan
Acrivon Therapeutics (ACRV) CDO receives 38,584-share RSU grant with staged vesting - Stock Titan
Acrivon (ACRV) COO Eric Devroe receives 72,981 RSU stock grant - Stock Titan
Acrivon Therapeutics (ACRV) leaders receive new RSU and stock grants - Stock Titan
Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock - simplywall.st
Acrivon (NASDAQ: ACRV) CLO has 184 shares withheld for RSU tax - Stock Titan
Acrivon Therapeutics (ACRV) CAO reports 99-share tax withholding on RSU vesting - Stock Titan
Acrivon (ACRV) CDO has 404 shares withheld to cover RSU tax liability - Stock Titan
[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity - Stock Titan
Acrivon (NASDAQ: ACRV) leaders use 1,743 shares for RSU tax withholding - Stock Titan
Maxim Group Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy - TipRanks
Number of shareholders of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Citadel affiliates disclose 13‑share stake in Acrivon (NASDAQ: ACRV) - Stock Titan
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer - The Globe and Mail
Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress By Investing.com - Investing.com India
Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress - Investing.com
H.C. Wainwright Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials - TipRanks
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts - Sahm
Key facts: ACRV ACR-368 ORR 39%; PD-1 combo P3 planned; Q1 loss $19M - TradingView
1.27%
1.43%
자본화:
|
볼륨(24시간):